Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston
3
×
boston blog main
boston top stories
clinical trials
3
×
life sciences
national blog main
3
×
allergan
crispr
cynthia collins
deals
editas medicine
gene editing
abbvie
alexion pharmaceuticals
alnylam pharmaceuticals
alzheimer's disease
boehringer ingelheim
dicerna pharamceuticals
drugs
fda
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
katrine bosley
leber congenital amaurosis
leber congenital amaurosis type 10
michelle robertson
national top stories
parkinson's disease
patisiran
rare diseases
rna interference
roche
san francisco blog main
voyager therapeutics
world health organization
What
gene
3
×
editas
editing
experimental
medicines
research
abbvie
allergan
alliance
biotech
blessing
bosley
caught
causing
ceo
check
clinical
crispr
cusp
depart
dicerna
disease
drug
exits
eye
genetic
hepatitis
humans
intended
katrine
medicine
million
pact
partner
partnership
pay
pharma
pharmaceuticals
producing
protein
Language
unset
Current search:
gene
×
boston
×
" national blog main "
×
biotech
×
" clinical trials "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial